Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder

Matcheri Keshavan, Mujeeb Shad, Paul Soloff, Nina Schooler

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Few treatment studies of schizotypal personality disorder (SPD) have investigated the new, atypical antipsychotic drugs. This study examined the efficacy and tolerability of olanzapine, an atypical antipsychotic drug, in a series of patients with DSM-IV diagnosed schizotypal personality disorder. Method: This was a 26-week, open-label study with flexible dose design in 11 subjects with a diagnosis of schizotypal personality disorder based on Structured Clinical Interview for DSM-IV (SCID) and Personality Disorder Examination (PDE Journal of Psychiatric Disorders 1 (1987) 1). Subjects were treated with a low dose (average 9.32 mg/day) of olanzapine. Psychopathology was assessed at baseline and at the end of the study and analyzed with last observation carried forward analysis. Results: Patients showed significant improvements in psychosis and depression ratings, as well as in overall functioning. Olanzapine was well tolerated, though significant weight gain was observed. Conclusion: This study provides preliminary data regarding olanzapine efficacy and tolerability in schizotypal personality disorder subjects. These data need to be confirmed in larger controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalSchizophrenia Research
Volume71
Issue number1
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

olanzapine
Schizotypal Personality Disorder
Diagnostic and Statistical Manual of Mental Disorders
Antipsychotic Agents
Personality Disorders
Controlled Clinical Trials
Therapeutics
Psychopathology
Psychotic Disorders
Weight Gain
Psychiatry
Observation
Interviews
Depression

Keywords

  • Efficacy
  • Olanzapine
  • Schizotypal personality disorder
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. / Keshavan, Matcheri; Shad, Mujeeb; Soloff, Paul; Schooler, Nina.

In: Schizophrenia Research, Vol. 71, No. 1, 01.11.2004, p. 97-101.

Research output: Contribution to journalArticle

Keshavan, Matcheri ; Shad, Mujeeb ; Soloff, Paul ; Schooler, Nina. / Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. In: Schizophrenia Research. 2004 ; Vol. 71, No. 1. pp. 97-101.
@article{894f75b01fbb4584940622ea5b6b5f50,
title = "Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder",
abstract = "Background: Few treatment studies of schizotypal personality disorder (SPD) have investigated the new, atypical antipsychotic drugs. This study examined the efficacy and tolerability of olanzapine, an atypical antipsychotic drug, in a series of patients with DSM-IV diagnosed schizotypal personality disorder. Method: This was a 26-week, open-label study with flexible dose design in 11 subjects with a diagnosis of schizotypal personality disorder based on Structured Clinical Interview for DSM-IV (SCID) and Personality Disorder Examination (PDE Journal of Psychiatric Disorders 1 (1987) 1). Subjects were treated with a low dose (average 9.32 mg/day) of olanzapine. Psychopathology was assessed at baseline and at the end of the study and analyzed with last observation carried forward analysis. Results: Patients showed significant improvements in psychosis and depression ratings, as well as in overall functioning. Olanzapine was well tolerated, though significant weight gain was observed. Conclusion: This study provides preliminary data regarding olanzapine efficacy and tolerability in schizotypal personality disorder subjects. These data need to be confirmed in larger controlled clinical trials.",
keywords = "Efficacy, Olanzapine, Schizotypal personality disorder, Tolerability",
author = "Matcheri Keshavan and Mujeeb Shad and Paul Soloff and Nina Schooler",
year = "2004",
month = "11",
day = "1",
doi = "10.1016/j.schres.2003.12.008",
language = "English (US)",
volume = "71",
pages = "97--101",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder

AU - Keshavan, Matcheri

AU - Shad, Mujeeb

AU - Soloff, Paul

AU - Schooler, Nina

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Background: Few treatment studies of schizotypal personality disorder (SPD) have investigated the new, atypical antipsychotic drugs. This study examined the efficacy and tolerability of olanzapine, an atypical antipsychotic drug, in a series of patients with DSM-IV diagnosed schizotypal personality disorder. Method: This was a 26-week, open-label study with flexible dose design in 11 subjects with a diagnosis of schizotypal personality disorder based on Structured Clinical Interview for DSM-IV (SCID) and Personality Disorder Examination (PDE Journal of Psychiatric Disorders 1 (1987) 1). Subjects were treated with a low dose (average 9.32 mg/day) of olanzapine. Psychopathology was assessed at baseline and at the end of the study and analyzed with last observation carried forward analysis. Results: Patients showed significant improvements in psychosis and depression ratings, as well as in overall functioning. Olanzapine was well tolerated, though significant weight gain was observed. Conclusion: This study provides preliminary data regarding olanzapine efficacy and tolerability in schizotypal personality disorder subjects. These data need to be confirmed in larger controlled clinical trials.

AB - Background: Few treatment studies of schizotypal personality disorder (SPD) have investigated the new, atypical antipsychotic drugs. This study examined the efficacy and tolerability of olanzapine, an atypical antipsychotic drug, in a series of patients with DSM-IV diagnosed schizotypal personality disorder. Method: This was a 26-week, open-label study with flexible dose design in 11 subjects with a diagnosis of schizotypal personality disorder based on Structured Clinical Interview for DSM-IV (SCID) and Personality Disorder Examination (PDE Journal of Psychiatric Disorders 1 (1987) 1). Subjects were treated with a low dose (average 9.32 mg/day) of olanzapine. Psychopathology was assessed at baseline and at the end of the study and analyzed with last observation carried forward analysis. Results: Patients showed significant improvements in psychosis and depression ratings, as well as in overall functioning. Olanzapine was well tolerated, though significant weight gain was observed. Conclusion: This study provides preliminary data regarding olanzapine efficacy and tolerability in schizotypal personality disorder subjects. These data need to be confirmed in larger controlled clinical trials.

KW - Efficacy

KW - Olanzapine

KW - Schizotypal personality disorder

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=4544269346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544269346&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2003.12.008

DO - 10.1016/j.schres.2003.12.008

M3 - Article

C2 - 15374577

AN - SCOPUS:4544269346

VL - 71

SP - 97

EP - 101

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -